The clinician-rated, 16-item Quick Inventory of Depressive Symptomatology (QIDS-C 16 ) has been extensively evaluated in patients with major depressive disorder (MDD). This report assesses the psychometric properties of the QIDS-C 16 in outpatients with bipolar disorder (BD, N = 405) and MDD (N = 547) and in bipolar patients in the depressed phase only (BD-D) (N = 99) enrolled in the Texas Medication Algorithm Project (TMAP) using classical test theory (CTT) and the Samejima graded item response theory (IRT) model.
Introduction
The Quick Inventory of Depressive Symptomatology (QIDS) includes 16 items that are contained within the 30-item Inventory of Depressive Symptomatology (IDS) (Rush et al., 2000; Rush et al., 2003a; Trivedi et al., 2004a) . These items were selected to measure the nine core symptom domains that defi ne a major depressive episode (DSM-IV) (APA, 2000) including Sleep (four items), Sad mood (one item), Appetite/weight change (four items), Concentration/decision-making (one item), Self view (one item), Thoughts of death or suicide (one item), General interest (one item), Energy level (one item), and Restlessness/agitation (two items) (Rush et al., 1986; Rush et al., 1996) . The severity of each of the nine criterion symptom domains is defi ned by the most pathological response in the item or set of items used to defi ne each domain.
There is considerable evidence for the reliability and validity of the QIDS-C 16 in patients with major depressive disorder (MDD) (Rush et al., 2003b; Rush et al., 2006a; Trivedi et al., 2004b) . The clinician-rated, 16-item Quick Inventory of Depressive Symptomatology (QIDS-C 16 ) can be administered in 5-7 minutes and therefore is costeffi cient. Cost and time effi ciency are especially important in the outpatient management of patients with major depressive disorder (MDD) and bipolar disorder (BD) (Chioqueta and Stiles, 2003) . The 16-item QIDS comes in three forms: self-report (QIDS-SR 16 ), clinician (QIDS-C 16 ), and interactive voice response ). These three forms yield highly similar results in outpatients with MDD (Rush et al., 2006a) . All three versions of the QIDS are also highly sensitive to treatment effects. This report evaluates the QIDS-C 16 in depressed outpatients with BD.
Several depression rating scales, including the Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Äsberg, 1979; Osterberg and Blaschke, 2005) , the Hamilton Rating Scale for Depression (Hamilton, 1960 (Hamilton, , 1967 Osterberg and Blaschke, 2005) , and the Bech-Rafaelsen Melancholia Scale (Bech and Rafaelsen, 1980) have been used to assess depressive symptom severity in patients with BD. The QIDS, however, focuses solely on the nine criterion symptom domains that defi ne a major depressive episode by DSM-IV (APA, 2000) . This focus is consistent with the aim of measuring remission (absence of the criterion symptoms for a major depressive episode), as suggested by the recent ACNP Task Force Report on remission (Rush et al., 2006c) . Since the QIDS comes in both clinician-rated and self-report versions, it is of interest to know how each of these measures performs in a bipolar sample.
This study addressed two questions: (a) what are the psychometric properties of the QIDS-C 16 in BD patients and (b) are there differences between BD patients and MDD patients in either the relative frequency of the various symptom domains that are endorsed or in the relation of the individual symptom domains to overall depression?
Methods and materials
Participants, design, and procedure All subjects in this report had either MDD or Bipolar I Disorder, including schizoaffective disorder-bipolar type. Participants were enrolled in the Texas Medication Algorithm Project (TMAP) (Rush et al., 2003b; Suppes et al., 2003) , whether in treatment as usual or the algorithm treatment group, as long as they had both a baseline and at least one post-baseline measure. Patients could be in the depressed, manic, or mixed phase. Patients were diagnosed by a traditional psychiatric clinical interview using DSM-IV criteria (APA, 1980) (see Gilbert et al., 1998; Rush et al., 2003b; Suppes et al., 2003; Trivedi et al., 2004b) conducted by practicing psychiatrists in the public sector. All diagnoses were checked with a checklist used by a Clinical Research Coordinator at each site. No structural interview was used. Subjects were outpatients at least 18 years of age. They had to be suffi ciently symptomatic as to require initiation of medication or a change in present type of medication. Most were on medications at baseline. Patients were enrolled at 19 outpatient clinics across Texas, as described in detail elsewhere (Suppes et al., 2003; Trivedi et al., 2004b) . Subjects who met criteria for schizoaffective disorder were divided into those with 'bipolar type' (included in the bipolar sample) and those with shizophrenic type (and excluded). This distinction was made based on the history of clear-cut manic or major depressive episodes with or without psychotic symptoms, in which some psychotic symptoms could persist outside the mood episodes (schizoaffective-bipolar type). For the bipolar-schizoaffective type, the affective episodes were mild and indistinct, present on top of a chronically psychotic course of illness. Patients who required inpatient hospitalization for detoxifi cation at study entry, or who were receiving mental retardation service or treatment in an Assertive Community Treatment program, or were not able to give informed consent were excluded. TMAP was conducted in accordance with international guidelines for good clinical practice and the Declaration of Helsinki and approved by the Institutional Review Boards at the University of Texas Southwestern Medical Center at Dallas and the University of Texas at Austin. All subjects provided written, informed consent prior to participation in the study. For these analyses, all enrollees with MDD or BD were included.
The QIDS-C 16 was obtained by extracting the 16 items that constitute the QIDS-C 16 from the 30-item clinicianrated Inventory of Depressive Symptomatology (IDS-C 30 ), which was obtained by Research Outcome Assessors (trained counselors, psychologists, social workers, or nurses) at baseline and every three months thereafter for up to 24 months. The QIDS-C 16 was scored as previously described (Rush et al., 2003a (Rush et al., , 2006b ) so that nine symptom domains are each rated 0-3. These nine domains refl ect the criterion symptoms required to diagnose a major depressive episode by DSM-IV (APA, 2000) . The range is 0-27, with no (0-5), mild (6-10), moderate (11-15), severe (16) (17) (18) (19) (20) , and very severe (21+) symptom severity.
Statistical methods
The psychometric properties of the QIDS-C 16 were evaluated at baseline and at exit by classical test theory (CTT) and the Samejima graded item response theory (IRT) methods (Samejima, 1997) as previously described (Rush et al., 2006b) . CTT analyses involved calculating the means and standard deviations of the nine symptom domains and computing the domain/total correlations (r it ) between these nine domains and the total score (sum of individual domain scores).
IRT analyses involved generating three dichotomies from the four response categories for each item (i.e. 0, 1, 2, 3). For each category, zero denotes the absence of symptomatology and three denotes severe symptomatology. The three dichotomies were (i) 0 versus 1, 2, or 3, (ii) 0 or 1 versus 2 or 3, and (iii) 0, 1, and 2 versus 3. For each domain, the analysis provided a common slope measure (a) and three location measures (b 0 , b 1 , and b 2 ). The slope measures, analogous to the item total correlation (r it ), describe the strength of relationship between each domain and overall depression. The three location measures, somewhat analogous to item means, describe symptom frequency. In particular, the larger the location estimate, the more often the less pathological categories (e.g. 0, 1 versus 2, 3) are used. For example, higher b 0 values are associated with less frequent endorsement of any of the three pathological categories (1, 2, or 3); the lower the b 0 value, the more commonly the symptom is reported.
IRT analysis entails an explicit method by which to compare diagnostic groups (e.g. BD versus MDD) with respect to one or more domains. This is accomplished by comparing a model in which one or more terms (a, b 0 , b 1 , and/or b 2 ) are constrained to equality between the groups with a model in which they are free to vary. A comparison of these two models generates a form of chi-square called G 2 . Signifi cance implies that the groups differ with respect to the term(s) studied. Such differences are known as differential item functioning (DIF). Slope differences imply that individual symptom domains relate differently to overall depression for BD and MDD patients. Location differences imply that symptoms are reported with different frequencies between the two groups. These analyses complement the CTT fi ndings of mean differences between groups.
IRT assumes that the nine QIDS domains vary unidimensionally. To establish unidimensionality in this sample, the obtained scree was compared with randomly generated scree values derived from the same number of observations, with a procedure known as parallel analysis (Horn, 1965; Humphreys and Ilgen, 1969; Humphreys and Montanelli, 1975; Montanelli and Humphreys, 1976) for the MDD, BD, and bipolar patients in the depressed phase only (BD-D) groups.
An important part of the IRT analysis is the generation of the test information function (TIF), which describes the sensitivity of the instrument to slight differences in depression over individuals with a range of depression severity as a function of depression level, which serves a similar role as coeffi cient alpha in CTT, but TIF is a function of depression level rather than an omnibus measure.
IRT analyses were performed using Multilog; the remaining analyses were performed using SAS.
Results

Sample features
Participants included 405 outpatients with BD and 547 outpatients with MDD. In the BD group, patients were in the depressed (BD-D) (99/405 = 24.4%), mixed (111/405 = 27.4%), or manic (113/405 = 27.9%) phases, and the BD group also included subjects with schizoaffective disorder, bipolar type (14.8%; 60/405), and another 5.4% (22/405) in an unspecifi ed phase. Two MDD patients with incomplete QIDS-C 16 data at exit were deleted from some analyses. The BD and MDD samples were 70% and 79% female, respectively. The BD sample was 9.4% AfricanAmerican, 27.7% Hispanic, 61.6% White, and 1.2% 'other.' The MDD sample was 20.8% African-American, 26.1% Hispanic, 51.7% White, and 1.3% 'other.' Overall, 19.4% of the MDD sample was psychotic, as was 34.1% of the BD sample. Generally, patients with BD were on public assistance (48.2%) and 81.3% graduated high school or had a General Educational Development (GED) credential. The comparable fi gures for MDD patients were 45.9% and 66.7% respectively.
Baseline versus exit CTT
Exit data were obtained at 3-24 months after study entry. The mean time from baseline to exit was 13.3 months [standard deviation (SD) = 4.6] for BD and 12.8 months (SD = 5.0) for MDD. The baseline and exit QIDS-C 16 means were 12.1 (SD = 5.8) and 10.1 (SD = 5.9), respectively, for the BD and 15.0 (SD = 5.5) and 11.8 (SD = 6.3), respectively for the MDD group. The decline in QIDS-C 16 scores within each group was signifi cant, t(404) = 6.88 (for BD) and t(544) = 11.27; p < 0.01 (for MDD). As might be expected, the QIDS-C 16 MDD means were signifi cantly greater than the BD means at both baseline and exit, t(950) = 7.88 and t(949) = 2.94; p < 0.01. The variance also increased within both groups from baseline to exit. The latter increases were associated with slightly increased coeffi cient alphas from 0.80 to 0.83 among the BD patients and 0.80 to 0.85 among the MDD patients from baseline to exit. a Includes bipolar patients in the depressed (n = 99), manic (n = 113), mixed (n = 111), and unspecifi ed (n = 22) phases at baseline as well as 60 schizoaffective patients. a Includes bipolar patients in the depressed (n = 99), manic (n = 113), mixed (n = 111), and unspecifi ed (n = 22) phases at baseline as well as 60 schizoaffective patients. Tables 1 and 2 also show the CTT fi ndings for individual domains. The decline from baseline to exit was found to be signifi cant beyond the 0.01 level for all individual domains except domain 1 (sleep disturbances) with BD patients. At baseline, the MDD patients tended to report greater symptom levels than the BD patients for all domains. At baseline, MDD patients also reported greater symptom levels in all but domains 1, 3, and 9 (Sleep, Appetite, and Restlessness/agitation) as compared to exit.
This analysis was repeated on only the 99 BD-D patients at baseline. Their scale mean was 14.5 (SD = 5.5). Coeffi cient alpha was 0.81, which was essentially identical to that obtained from the full BD patient sample (0.80). The MDD group averaged 0.5 units higher in their total score at baseline than the BD-D patients, which was nonsignifi cant. The only difference between the BD-D and MDD patients in individual QIDS-C 16 domains was for Sad mood t(641) = 3.03, p < 0.01. MDD patients tended to report greater levels of sad mood. This analysis could not be performed at exit since exit phase was unknown.
Dimensionality
Figure 1 (top panel) compares the baseline and exit screes obtained from the full BD (top panel) sample with randomly generated scree; the BD-D group (middle panel), and the MDD group (bottom panel). In all groups, the obtained fi rst principal component was much larger than its randomly generated counterpart. The reverse was true of the second component. These results confi rm the unidimensionality of the QIDS-C 16 in the BD, BD-D, and MDD groups at both baseline and exit.
IRT analyses
Slope differences were fi rst assessed by an overall test comparing a model in which all nine pairs of a parameters for the BD and MDD groups were allowed to vary freely and a model in which these nine pairs were constrained to equality, allowing all of the 27 intercept parameters (nine domains × three intercepts/domain) to vary freely in both models. The two models did not differ signifi cantly either at baseline or at exit, G 2 (9) = 7.6 and 8.8. This equality means that each slope can be assumed to have the same value within the two groups, i.e. the domains are equally discriminating within BD and MDD patients. Next, intercept differences were evaluated by comparing a model in which the 27 pairs of intercepts were allowed to vary freely versus a model in which they were constrained to equality, allowing the slopes to vary freely in both cases. Differences were clearly signifi cant at baseline and at exit, G 2 (27) = 111.3 and 90.2; p < 0.001, respectively, justifying tests on individual domains.
Differences between BD and MDD intercepts were signifi cant for all individual domains beyond the 0.01 level at baseline save for domains 3 (Concentration/decision making, p < 0.05) and 9 [Restlessness/agitation, non-signifi cant (ns)]. At exit, domains 2 (Sad mood), and 8 (Energy level) were signifi cant beyond the 0.01 level. Domains 4 (Concentration/decision making), 5 (Self view), and 6 (Thoughts of death or suicide) were significant beyond the 0.05 level, and domains 1 (Sleep), 3 (Appetite/weight), 7 (General interest), and 9 (Restlessness/agitation) were non-signifi cant. Paralleling the fi nding that MDD patients tended to report higher levels of symptomatology than BD patients, MDD thresholds were lower in 26 of 27 comparisons at baseline and 24 of comparisons 27 at exit.
When only the BD-D patients were compared to MDD patients, the baseline slope differences were again nonsignifi cant, G 2 (9) = 6.1, but the intercept differences were signifi cant, G 2 (27) = 41.1, p < 0.01. The only baseline intercept to differ signifi cantly was domain 2 (Sad mood, p < 0.05). In other words, the rather pronounced threshold differences observed when all BD patients were compared with the MDD patients was due to the fact that most of the BD patients were not in a depressed mood. When the comparison was limited to depressed patients, group differences were minimal. Figure 2 contains the TIFs for the QIDS-C 16 at baseline and at exit. Data for the full BD sample (top panel), the depressed phase or BD-D only sample (n = 99), and the MDD patients (bottom panel) are shown. The function peaks above the means of BD distributions but near the mean of the MDD patients. This fi nding refl ects the mean difference between BD and MDD groups and suggests that the test is most sensitive to detecting differences for MDD patients at an average level of depression which is similar to BD-D patients.
Test information functions (TIFs)
Subgroup differences within BD sample
Data were available as to phase of illness (depressed, manic, mixed, schizoaffective, or other) for the BD patients, and as to subtype (non-psychotic and psychotic) for the MDD patients. Differences in overall QIDS-C 16 scores varied signifi cantly among the BD patient groups, F(4 404) = 9.45. The BD-D patients had the highest means; patients in a manic phase had the lowest means. Figure 3 presents these QIDS-C 16 means +1 standard deviation for each subgroup, respectively. Conversely, psychotic and non-psychotic MDD patients did not differ with respect to their QIDS-C 16 means, F(1 539) = 3.75.
Discussion
These results indicate that (i) the psychometric properties of the QIDS-C 16 are satisfactory in BD patients overall and in BD-D (BD-depressed phase only) patients, (ii) the QIDS-C 16 is unidimensional for BD, BD-D, and MDD groups, and (iii) the relation between these symptom domains to overall depression is highly similar for MDD and BD patients, and were very similar for BD-D and MDD patients. The psychometric properties of the QIDS-C 16 in the full BD and in the BD-D samples were very similar to those previously found with MDD patients. These results confi rm prior fi ndings (Rush et al., 2005; Rush et al., 2006b; Trivedi et al., 2004a) for patients with MDD indicating that the QIDS-C 16 is a valid measure of depression.
These fi ndings apparently contradict some previous research that has suggested the need for different scales to assess depression severity in each disorder, most specifi cally Berk et al. (2004) . However, Berk et al.'s (2004) review discussed symptoms other than those constituting the depressive core, e.g. symptoms of atypical depression, and also dealt with other differences between MDD and BD such as age of onset. Our assertion based upon the present data is that one cannot use the core symptoms of depression to differentiate MDD and BD. In the present study, BD patients overall tended to report less symptom severity than MDD patients, but the relation between each domain and overall depression was the same for both groups. That severity is lower in a mixed BD sample is expected. When the BD-D only sample was evaluated, severity was comparable to the MDD sample. Thus, we do not feel that there is need for a scale to measure core depressive symptoms separately for BD patients. Symptoms found in subgroups of patients are a separate issue.
Limitations
One possible limitation is that both TMAP groups are of limited education, so the fi ndings may not generalize to a better educated sample. However, it is just as possible that the limited education may be a benefi t since the QIDS-C 16 may work even better on a better educated BD sample. Our previous fi ndings in patients with MDD showed that the QIDS worked about equally well on a better educated sample (Rush et al., 2005; Rush et al., 2006b; Trivedi et al., 2004a) . Whether the same is true for a better educated BD sample remains to be evaluated.
A second limitation is that the QIDS-C 16 was extracted from the full IDS-C 30 , so the context provided by those items in the IDS-C 30 that are not part of the QIDS-C 16 may have been benefi cial to the psychometric properties of the QIDS-C 16 .
A third limitation is that patients could be taking any medication at baseline or exit, which, in turn, could affect the symptom profi les found. Thus, psychometric assessment in a medication-free bipolar sample has yet to be accomplished.
These results are limited to the QIDS-C 16 . Whether similar results would pertain to the self-report or interactive voice versions of the QIDS is unknown. However, the results obtained with the QIDS-C 16 and self-report versions have yielded highly similar results with MDD patients (Rush et al., 2005; Rush et al., 2006a; Rush et al., 2006b; Trivedi et al., 2004b) .
Finally, we did not compare the QIDS-C 16 to other depression scales in this study. Such comparisons are indicated.
Conclusion
These results support the use of the QIDS-C 16 to assess depression in BD patients. Taken with other reports (Trivedi et al., 2004a) , the QIDS-C 16 can be reliably used in studies of patient samples that include both patients with MDD and BD.
